Salvage chemotherapy after failure of targeted therapy in a child with BRAF V600E low-grade glioma

Pediatr Blood Cancer. 2021 Jan;68(1):e28561. doi: 10.1002/pbc.28561. Epub 2020 Jul 18.

Authors

Musthafa Raswoli¹, Liana Nobre¹, Cynthia Hawkins², Ute Katharina Bartels¹, Uri Tabori¹, Eric Bouffet¹

Affiliations

¹ Division of Haematology/Oncology, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
² Department of Laboratory Medicine and Pathobiology, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.

PMID: 32681754
DOI: 10.1002/pbc.28561

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Brain Neoplasms / drug therapy*
Brain Neoplasms / genetics
Brain Neoplasms / pathology
Child, Preschool
Glioma / drug therapy*
Glioma / genetics
Glioma / pathology
Humans
Lomustine / administration & dosage
Male
Molecular Targeted Therapy
Mutation*
Procarbazine / administration & dosage
Prognosis
Proto-Oncogene Proteins B-raf / genetics*
Salvage Therapy*
Thioguanine / administration & dosage
Vincristine / administration & dosage

Substances

Procarbazine
Vincristine
Lomustine
BRAF protein, human
Proto-Oncogene Proteins B-raf
Thioguanine